newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON, Mass., Nov. 10,